EyePoint Pharmaceuticals, Inc. entered into an underwriting agreement for a public offering of its common stock, expecting to raise approximately $215.9 million to advance clinical development and support pipeline development initiatives.
AI Assistant
EYEPOINT PHARMACEUTICALS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.